Practical considerations for genomic testing in colorectal cancer

Stacey Cohen, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on how genomic testing for molecular aberrations can influence treatment approaches in colorectal cancer. Liquid biopsies enable monitoring of multiple ctDNA mutations of varying frequencies, which can ultimately inform clinicians when a treatment regimen should be changed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.